Sweden bolsters biotech
Enlarge image

BusinessSweden

Sweden bolsters biotech

05.04.2012 - Swedish pharma company Astra Zeneca plus Wallenberg Foundation and Swedish government pledge a record investment into the biotech industry.

Stockholm – Under a new initiative, AstraZeneca will invest €2.3m to €4.5m (SEK20m to SEK40m) a year over the next five years in early-stage research projects. The Wallenberg Foundation, a private financing institution which is dedicated to promoting scientific research and education in Sweden, will provide additional €25m (SEK220m). The money will be used to build up technology laboratories for the SciLifeLab collaboration between four Swedish universities. The contribution of the Swedish government is yet unknown, but a spokesperson already announced the government is planning a record investment in the country's life science infrastructure. The details would be published in the autumn budget. Jan Björklund, the Swedish Minister for Education, announced the SciLifeLab will become a national research institute for major research in molecular biosciences and bioinformatics. According to the government’s plan, SciLifeLab will grow to employ about 1,000 scientists and have a turnover of about €113m (SEK1bn) within a few years.  SciLifeLab is a joint venture between four universities; Karolinska Institutet, the Royal Institute of Technology, Stockholm University and Uppsala University. The medical research focuses on investigating the molecular basis of complex human diseases, and seeks to find biomarkers that can help diagnose diseases and monitor their progress. The vision is to make SciLifeLab a competitive centre for high-throughput biosciences with platforms in genomics, comparative genetics, proteomics, bioimaging and functional genomics as well as research communities in biology, medicine and environmental sciences.

.

http://www.european-biotechnology-news.com/news/news/2012-02/sweden-bolsters-biotech.html

EU

04.09.2015 Crowdfinancing has just recently emerged as a financing instrument in the Life Sciences. A new report lists 42 European companies in the sector that have raised a total of almost €23m.

DiabetesFrance

01.09.2015 Sanofi is partnering up with Google’s life sciences team with an ambitious goal: to change the face of diabetes management.

M&ASwitzerlandFrance

31.08.2015 In order to boost its active cosmetic ingredients business, the Swiss flavour and fragrance giant Givaudan has acquired Volketswil-based Induchem Holding and all its subsidiaries.

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • EVOLVA (CH)1.49 CHF12.03%
  • TIGENIX (B)1.23 EUR9.82%
  • OREXO (S)49.10 SEK8.39%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)11.35 SEK-11.67%
  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • PROTHENA PLC (IE)52.70 USD-6.54%

TOP

  • KARO BIO (S)41.90 SEK2568.8%
  • BIOTECH PHARMACON (N)16.80 NOK80.6%
  • TRANSGENE (F)4.86 EUR75.5%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • NEUROVIVE PHARMACEUTICAL AB (S)11.35 SEK-49.6%
  • THROMBOGENICS (B)2.85 EUR-42.1%

TOP

  • KARO BIO (S)41.90 SEK4661.4%
  • ADOCIA (F)89.30 EUR409.1%
  • GALAPAGOS (B)53.25 EUR325.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)11.35 SEK-81.7%
  • BIOTEST (D)20.30 EUR-76.5%

No liability assumed, Date: 03.09.2015